Back to Browse Journals » Drug Design, Development and Therapy » Volume 6

Imiglucerase in the treatment of Gaucher disease: a history and perspective

Authors Deegan PB, Cox TM

Published Date April 2012 Volume 2012:6 Pages 81—106

DOI http://dx.doi.org/10.2147/DDDT.S14395

Received 14 November 2011, Accepted 15 December 2011, Published 18 April 2012

Patrick B Deegan, Timothy M Cox
Department of Medicine, University of Cambridge, Lysosomal Disorders Unit, Addenbrooke's NHS Foundation Hospitals Trust, Cambridge, UK

Abstract: The scientific and therapeutic development of imiglucerase (Cerezyme®) by the Genzyme Corporation is a paradigm case for a critical examination of current trends in biotechnology. In this article the authors argue that contemporary interest in treatments for rare diseases by major pharmaceutical companies stems in large part from an exception among rarities: the astonishing commercial success of Cerezyme. The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease.

Keywords: enzyme therapy, ultra-orphan, macrophage targeting, lysosomal disease, mannose lectin, biopharmaceutical

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Gaucher disease: clinical profile and therapeutic developments

Timothy M Cox

Biologics: Targets and Therapy 2010, 4:299-313

Published Date: 6 December 2010

Readers of this article also read:

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod

Hanson KA, Agashivala N, Stringer SM, Balantac Z, Brandes DW

Patient Preference and Adherence 2013, 7:309-318

Published Date: 16 April 2013

Ruxolitinib as an emerging treatment in myelofibrosis

Emanuel RM, Geyer HL, Mesa RA

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:11-18

Published Date: 9 March 2013

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Vascular Health and Risk Management 2013, 9:21-28

Published Date: 23 January 2013

Efficacy of retinol palmitate eye drops for dry eye in rabbits with lacrimal gland resection

Odaka A, Toshida H, Ohta T, Tabuchi N, Koike D, Suto C, Murakami A

Clinical Ophthalmology 2012, 6:1585-1593

Published Date: 1 October 2012

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T

ClinicoEconomics and Outcomes Research 2012, 4:227-235

Published Date: 23 August 2012

Synthesis, characterization, and in vivo efficacy evaluation of PGG–docetaxel conjugate for potential cancer chemotherapy

Yang D, Van S, Shu Y, Liu X, Ge Y, Jiang X, Jin Y, L Yu

International Journal of Nanomedicine 2012, 7:581-589

Published Date: 3 February 2012